2022-01-24 19:34Financial Performance & Growth - BeiGene reported $962 million in Q3 year-to-date revenue from product sales and collaborations[7] - The company's product revenue growth showed a +109% year-over-year increase[58] - Specifically, product revenue in North America grew by +111% year-over-year, reaching $192.5 million in Q3 2021 and $437.2 million for the period of 1Q-3Q 2021[58] - BeiGene has a strong cash position of $7.6 billion, including Q3 2021 cash balance, STAR net proceeds, and Novartis TIGIT upfront payment[7, 63] Pipeline & Clinical Development - BeiGene has approximately 50 assets in clinical and commercial stages[7] - The company has initiated over 100 clinical trials across 45 markets[7, 22] - Zanubrutinib demonstrated a 24-month Progression-Free Survival (PFS) rate of 85.5% compared to 69.5% for Bendamustine + Rituximab (BR) in the SEQUOIA Phase 3 study in 1L CLL[40] - In the ALPINE Phase 3 study of Zanubrutinib vs Ibrutinib in R/R CLL/SLL, Zanubrutinib showed an Overall Response Rate (ORR) of 78.3% compared to 62.5% for Ibrutinib (p < 0.001)[45] Collaborations & Commercialization - BeiGene's PD-1 and TIGIT collaborations with Novartis included nearly $1 billion in upfront payments[16] - The company retains rights to PD-1 and TIGIT to drive broad access for 6.6 billion people in its territories[52, 60] - Brukinsa has been approved in 43 markets by 16 regulatory authorities[7, 57] - BeiGene's global commercial team consists of 3,400+ professionals[7, 9, 58]